Funding
Series A · Biotech

Fathom Therapeutics raises $47m Series A for drug design

Sutter Hill Ventures, Chemistry, Alexandria Venture Investments and NY Ventures participated in the round.

Updated Oct 16, 2026By RoundOS Funding desk

Fathom Therapeutics raised $47 million in Series A financing on April 27. Participants included Sutter Hill Ventures, Chemistry, Alexandria Venture Investments and Empire State Development's NY Ventures. The company combines quantum chemistry and AI to design drug molecules.

Funding history

Series A · This round$47M

Sources

  1. Fathom Therapeuticsprojectstartups.com
  2. prnewswire.com

Similar rounds

All Biotech rounds →
Guoke Brain-Computer

Beijing startup developing non-invasive wearable brain-computer interfaces that combine brain-signal detection, decoding and neural modulation.

UndisclosedSeed · Oct 23, 2026
Star Therapeutics

Biotechnology company discovering and developing antibody therapies for diseases with significant unmet need.

$200MPrivate financing · Oct 23, 2026
Pathos AI

Clinical-stage drug developer using AI to select therapeutic assets and guide oncology trials.

$237MSeries E · Oct 23, 2026
Knowledge Work

Tokyo software company developing sales AI agents, an agent operating platform and consulting services for enterprise sales teams.

¥4.8BSeries C debt second close · Oct 23, 2026

Related